Acebutolol
beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM
Also known as: (+/-)-Acebutolol, (RS)-Acebutolol, acebutolol HCl, acebutolol hydrochloride, dl-Acebutolol, IL-17803A
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Acebutolol is an ofp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1984. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 3 molecular targets, including ADRB1, ADRB2 and Htr1a. Recorded indications include Hypertensive disorder and Ventricular premature beats.
- Approval status: ofp (first approved 1984 by the FDA).
- Drug class: beta-Adrenergic Blocker.
- Mechanism of action: Adrenergic beta-Antagonists.
- Molecular targets: ADRB1, ADRB2 and Htr1a (3 listed in DrugCentral).
- Indications: Hypertensive disorder and Ventricular premature beats.
- ATC code: C07AB04 (Beta blocking agents, selective).
- Molecular formula: C18H28N2O4; molecular weight 336.43 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Hypertensive disorder
- Ventricular premature beats
Off-label uses (5)
- Angina pectoris
- Anxiety
- Mitral valve prolapse
- Myocardial Reinfarction Prevention
- Thyrotoxicosis
Contraindications (22)
- Acute exacerbation of asthma
- Anaphylaxis
- Asthma
- Cardiogenic shock
- Complete atrioventricular block
- Decompensated cardiac failure
- Depressive disorder
- Diabetes mellitus
- Disease of liver
- Kidney disease
- Myasthenia gravis
- Partial atrioventricular block
- Peripheral arterial occlusive disease
- Peripheral vascular disease
- Pheochromocytoma
- Pregnancy, function
- Psoriasis
- Pulmonary emphysema
- Raynaud's phenomenon
- Severe chronic obstructive pulmonary disease
- Sick sinus syndrome
- Sinus bradycardia
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic beta-Antagonists |
|---|---|
| Established pharmacologic class | beta-Adrenergic Blocker |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-1 adrenergic receptor | ADRB1 | antagonist | Ki 7.30 |
| Beta-2 adrenergic receptor | ADRB2 | unknown | Ki 6.40 |
| 5-hydroxytryptamine receptor 1A | Htr1a | unknown | Ki 5.00 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1984-12-28 | FDA | — | PROMIUS PHARMA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C07AB04 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, selective |
C07BB04 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS AND THIAZIDES › Beta blocking agents, selective, and thiazides |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Sedation complication | 1819.7 |
| Creatinine renal clearance decreased | 1805.2 |
| Cognitive disorder | 1727.7 |
| Orthostatic hypotension | 1678.2 |
| Blood calcium decreased | 1567.3 |
| Sedation | 1521.5 |
| Balance disorder | 1369.2 |
| Depressed level of consciousness | 1140.7 |
| Hypotension | 859.3 |
| Mobility decreased | 832.1 |
| Constipation | 795.8 |
| Fall | 735.4 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Acebutolol is on its molecule page.
| Molecular formula | C18H28N2O4 |
|---|---|
| Molecular weight | 336.43 g/mol |
| CAS number | 37517-30-9 |
| InChIKey | GOEMGAFJFRBGGG-UHFFFAOYSA-N |
| PubChem CID | 1978 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Acebutolol used for?
DrugCentral lists the following indications for Acebutolol: Hypertensive disorder and Ventricular premature beats.
How does Acebutolol work?
Acebutolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB1 (antagonist), ADRB2 and Htr1a.
When was Acebutolol first approved?
Acebutolol was first approved by the FDA in 1984.
What drug class does Acebutolol belong to?
Acebutolol is in the beta-Adrenergic Blocker class.
What is the chemical formula of Acebutolol?
Acebutolol has the molecular formula C18H28N2O4 and a molecular weight of 336.43 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 40 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200813 — compound record and bioactivity
- PubChem CID 1978 — chemical identifiers
- DrugBank DB01193 — drug record
- FDA UNII 67P356D8GH — substance identity
- DailyMed: FDA labels for Acebutolol — current prescribing information (label search)
- UniProt P08588 (ADRB1) — target protein
- UniProt P07550 (ADRB2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.